There are 3 classes of receptors for the Fc region of IgG (FcγRs): FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16), each with multiple isoforms.  All these receptors are members of the Ig superfamily (IgSF) and they play important roles in the activation or inhibition of immune responses. FcγRI is a high-affinity receptor for IgG while both FcγRII and FcγRIII are low-affinity receptors that bind IgG in the form of immune complexes.  There are two genes for human FcγRIII: A (CD16A) that encodes a single pass transmembrane receptor and B (CD16B) that encodes a GPI-anchored protein. The extracellular domains (ECDs) of CD16A and CD16B share 97% amino acid sequence homology.  CD16A is expressed on most effector cells of the immune system including macrophage, monocyte, NK cells, mast cells, eosinophils, dendritic cells and Langerhans cells. Signaling through CD16A results in oxidative burst, cytokine release and phagocytosis by macrophages, antibody-dependent cellular cytotoxicity by natural killer cells and degranulation of mast cells as well as clearance of immune complexes.  In humans, a single nucleotide polymorphism creates high Fc-binding (176V) and low Fc-binding (176F) forms that, when homozygous, may influence susceptibility to autoimmune diseases or response to therapeutic IgG antibodies. CD16A surface expression requires interaction of an accessory chain, either the common gamma-chain or CD3zeta. A soluble form of CD16A can be produced by proteolytic cleavage and circulates in plasma, which is increased in rheumatoid arthritis and in coronary artery diseases.

There are 3 classes of receptors for the Fc region of IgG (FcγRs): FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16), each with multiple isoforms.  All these receptors are members of the Ig superfamily (IgSF) and they play important roles in the activation or inhibition of immune responses. FcγRI is a high-affinity receptor for IgG while both FcγRII and FcγRIII are low-affinity receptors that bind IgG in the form of immune complexes.  There are two genes for human FcγRIII: A (CD16A) that encodes a single pass transmembrane receptor and B (CD16B) that encodes a GPI-anchored protein. The extracellular domains (ECDs) of CD16A and CD16B share 97% amino acid sequence homology.  CD16A is expressed on most effector cells of the immune system including macrophage, monocyte, NK cells, mast cells, eosinophils, dendritic cells and Langerhans cells. Signaling through CD16A results in oxidative burst, cytokine release and phagocytosis by macrophages, antibody-dependent cellular cytotoxicity by natural killer cells and degranulation of mast cells as well as clearance of immune complexes.  In humans, a single nucleotide polymorphism creates high Fc-binding (176V) and low Fc-binding (176F) forms that, when homozygous, may influence susceptibility to autoimmune diseases or response to therapeutic IgG antibodies. CD16A surface expression requires interaction of an accessory chain, either the common gamma-chain or CD3zeta. A soluble form of CD16A can be produced by proteolytic cleavage and circulates in plasma, which is increased in rheumatoid arthritis and in coronary artery diseases.

 

Product Details

 

Gene Symbol: CD16A; FCGR3A; FCG3; CD16; FCGR3; IGFR3; IMD20; FCR-10; FCRIII; FCGRIII; FCRIIIA

 

NCBI Gene ID: 2214

 

Uniprot Entry: P08637

 

Construct Details: The recombinant human CD16A-Fc is expressed as a 420-amino acid protein consisting of Gly17 -  Gln208 region of CD16A-V176 and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions.   

 

Source: Human cells stably expressing human CD16A-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

        10         20         30         40         50         60 

GMRTEDLPKA VVFLEPQWYR VLEKDSVTLK CQGAYSPEDN STQWFHNESL ISSQASSYFI 

        70         80         90        100        110        120 

DAATVDDSGE YRCQTNLSTL SDPVQLEVHI GWLLLQAPRW VFKEEDPIHL RCHSWKNTAL 

       130        140        150        160        170        180 

HKVTYLQNGK GRKYFHHNSD FYIPKATLKD SGSYFCRGLV GSKNVSSETV NITITQGLAV 

       190        200        210        220        230        240 

STISSFFPPG YQSTGTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS 

       250        260        270        280        290        300 

HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA 

       310        320        330        340        350        360 

LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP 

       370        380        390        400        410        420 

ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 

 

M.W.: Calculated molecular mass (kDa): 47.4; Estimated by SDS-PAGE under reducing condition (kDa): 50-55 

 

Calculated PI: 6.74

 

Calculated extinction coefficients (M-1 cm-1, at 280nm): 76945

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above)

 

Formulation: Supplied at 0.5 mg/ml in sterile PBSpH7.4 (carrier & preservative free). 

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method 

 

Bioactivity: Binds human IgG or Fc-fusion proteins as measured by a functional ELISA with low affinity

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 6 months. 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Immunol. Today 14:215 (1993).

2. J Biol Chem. 270 (43): 25762 (1995)

3. J. Immunol. 157:1184 (1996)

4. Annu. Rev. Immunol.19:275 (2001).

5. Nature Rev. Immunol. 2:580 (2002)

 

 

 

Additional supporting documents, including PDS, COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.